The progress in the research of antiplatelet agents (1995-2017).

about

The progress in the research of antiplatelet agents (1995-2017).

Item

http://www.wikidata.org/entity/Q38669003

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The progress in the research of antiplatelet agents (1995-2017).

@en

type

Item

label

The progress in the research of antiplatelet agents (1995-2017).

@en

prefLabel

The progress in the research of antiplatelet agents (1995-2017).

@en

P1476

The progress in the research of antiplatelet agents (1995-2017).

@en

P2093

Lulu Zhao

http://www.w3.org/2001/XMLSchema#string

Oscar Benimana

http://www.w3.org/2001/XMLSchema#string

Yi Kong

http://www.w3.org/2001/XMLSchema#string

Zhiyu Li

http://www.w3.org/2001/XMLSchema#string

Zhouling Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Closed headpiece of integrin IIb 3 and its complex with an IIb 3-specific antagonist that does not induce opening

Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes

Aspirin resistance may increase death risk in some patients with heart disease

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans

Targeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects

P304

1087-1110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/FMC-2017-0001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28632424

http://www.w3.org/2001/XMLSchema#string